Home » Wenting Zhang

Wenting Zhang

Senior Manager

Wenting Zhang, PhD, is a Senior Manager at CBPartners. Wenting supports engagement work across a variety of practices with primary focus on Value, Access, and Pricing.

Connect with Wenting Zhang

wenting.zhang@cbpartners.com

LinkedIn

Published Articles

ISPOR Asia-Pacific 2020: Comparison of Healthcare Systems and Opportunities for Innovative Drugs Across India, Vietnam, and Indonesia

A research poster that aims to understand how various healthcare system archetypes in APAC markets (e.g., India, Vietnam, and Indonesia) lead to access for high-cost innovative oncology treatments.

ISPOR Asia-Pacific 2020: Dancing with the Dragon – Considerations and Learnings in the 2019 China NRDL Negotiations

A research poster that aims to evaluate the outcomes of the 2019 NRDL negotiations involving PDx inhibitors and DAA products.

ISPOR Asia-Pacific 2020: China’s 2019 NRDL Update – Implications on Global & Local Manufacturer Strategy

A research poster to evaluate 2019 NRDL negotiation outcomes as indicators of potential strategic approaches for multinational and domestic manufacturers to achieve NRDL listing.

2019 NRDL: Insights for Future Pricing Negotiations in China

The 2019 NRDL update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas. CBPartners' blog post examines how these learnings can help shape future NRDL negotiations.

China: There’s a New NRDL in Town

Since the Chinese government brought a deluge of reforms to their pharmaceutical sector in 2018, it is no surprise 2019 is shaping up to be another game-changing year. CBPartners' Asia-Pacific Center of Excellence delivered insights about the evolving NRDL in China, as well as strategic considerations for pharmaceutical manufacturers.

China: Awakening the Pharmaceutical Innovation Giant

Evolving Reimbursement Dynamics in China

When the engine of innovation gets the green light of marketing authorisation, it is typically first in the USA, and sometimes for the EMA’s (European Medicines Agency) jurisdiction over much of Europe. Unfortunately, China is too often one the last markets among the major and highest-tier of emerging markets to be considered for broad patient access. CBPartners explores the evolving reimbursement dynamics in China.